Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...

The Patent Trial and Appeal Board agreed with Pfizer and its German partner that Moderna's patents were invalid based on "prior art" that disclosed the inventions before Moderna patented them. The ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Dr. Jay Bhattacharya told Sen. Josh Hawley that he supports developing alternatives for vaccines and therapeutics that use aborted cell lines.

Indigenous peoples have been on a “path to unprecedented progress” after the first talks in Cali adopted a new program of ...